Structural insights into interaction mechanisms of alternative piperazine-urea YEATS domain binders in MLLT1
X. Ni, D. Heidenreich, T. Christott, J. Bennett, M. Moustakim, P. Brennan, O. Fedorov, S. Knapp, A. Chaikuad
Abstract
YEATS-domain-containing MLLT1 is an acetyl/acyl-lysine reader domain, which is structurally distinct from well-studied bromodomains and has been strongly associated in development of cancer. Here, we characterized piperazine-urea derivatives as an acetyl/acyl-lysine mimetic moiety for MLLT1. Crystal structures revealed distinct interaction mechanisms of this chemotype compared to the recently described benzimidazole-amide based inhibitors, exploiting different binding pockets within the protein. Thus, the piperazine-urea scaffold offers an alternative strategy for targeting the YEATS domain family.
02 /Specification & Classification
Click any tag to browse matching papers- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Structure and inhibitor binding characterization of oncogenic MLLT1 mutants
X. Ni, A. T. Londregan, … A. Chaikuad·bioRxiv·Feb 8, 2021
- A structure-based approach towards identification of inhibitory fragments for eleven-nineteen-leukemia protein (ENL) YEATS domain
D. Heidenreich, M. Moustakim, … S. Knapp·bioRxiv·Nov 8, 2018
- Conformational and Thermodynamic Differences Underlying Wild-type and Mutant ENL YEATS Domain Specificity for Epigenetic Marks
L. Baweja, J. Wereszczynski·bioRxiv·Jul 14, 2022
- Phage-Assisted, Active Site-Directed Ligand Evolution with a Genetically Encoded Nε-Butyryl-ʟ-Lysine to Identify a Cellularly Potent and Selective Inhibitor for the ENL YEATS Domain as an Anti-Leukemia Agent
P.-H. C. Chen, X. S. Guo, … W. R. Liu·bioRxiv·Jan 8, 2023
- Structural basis of anticancer drug recognition and amino acid transport by LAT1
- The Prioritization of Eleven-Nineteen-Leukemia Inhibitors as Potential Drug Candidates to Treat Acute Myeloid Leukemia
X. S. Guo, P.-H. C. Chen, … W. R. Liu·bioRxiv·Dec 7, 2022